VivoSeq
Oncology

Colon Adenocarcinoma

23

Pipeline Programs↗

7

Active Trials↗

13

Companies Involved↗

Colon Adenocarcinoma is an emerging landscape with 23 programs across 13 companies. The most active players are Taiho Oncology, Inc., Pfizer, INSYS Therapeutics Inc. 6 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

19/100

Mech. Concentration

15/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

1 program

Phase 1Pfizer logo

Pfizer

2 programs

Phase 1I

INSYS Therapeutics Inc

1 program

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2Merck & Co. logo

Merck & Co.

4 programs

Phase 3E

Eastern Cooperative Oncology Group

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

15 of 21 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody629%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 91% of 23 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting5 · 71%
Active, not recruiting2 · 29%

Clinical Trials

Trial Activity

7 trials

Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
Recruiting·—·Phase 2·NCT07468630·106 enrolled
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Recruiting·UUniversity of California, Irvine·Phase 1·NCT04920032·22 enrolled
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06997497·477 enrolled
Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer
Recruiting·Alliance for Clinical Trials in Oncology·Preclinical·NCT07143487·4,186 enrolled
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Recruiting·CCity of Hope Medical Center·Phase 2·NCT07595874·100 enrolled
Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer
Active, not recruiting·Alliance for Clinical Trials in Oncology·Preclinical·NCT05710406·1 enrolled
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02912559·712 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)